Stéphane Bancel, AP Images

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

For­get what you’ve heard in re­cent weeks about mil­lions, or even po­ten­tial­ly hun­dreds of mil­lions of dos­es of vac­cines to be made in the near term to fight the pan­dem­ic. To­day, the goal is set on the bil­lion-dose mark, and Mod­er­na $MR­NA has moved the last man­u­fac­tur­ing piece in place to hit the mark.

Ear­ly Fri­day the Boston-based mR­NA play­er, which has the most ad­vanced US vac­cine in the clin­ic, an­nounced a deal with Lon­za cre­at­ing a 10-year al­liance on vac­cine pro­duc­tion, start­ing with mR­NA-1287, head­ed in­to Phase II in a fast-paced tri­al pro­gram aimed at boot­ing up a near-term ap­proval that could land in a mat­ter of months — rough­ly the R&D equiv­a­lent of tak­ing a cross-coun­try stock car race and pow­er­ing the ve­hi­cles with rock­et en­gines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.